Adults 18 to 24, any sex, with Tobacco Use or Cigar Smoking. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Subjective Rewarding Value of Cigarillo FlavoringPrimary· Laboratory visit 1 (Day 1, 1.5 hours)
Subjective rewarding value of cigarillo flavoring will be measured with the Cigarette Evaluation Scale (CES) adapted for cigarillo use. The CES is an 11 item Likert-format (1=not at all to 7=extremely) self-report instrument with established validity and reliability (α \> .80). The investigators will focus on the sum of the two-item satisfaction subscale ("Was it satisfying?" and "Did it taste good?") to calculate the subjective rewarding value. The minimum possible score is 2 and the maximum is 14. Higher scores denote greater subjective rewarding value. Primary Outcome measured at visit 1.
Citrus "Jazz"
Group
Value
95% CI
Flavor
4.03
± 1.47
Cream
Group
Value
95% CI
Flavor
3.63
± 1.42
Non-flavored
Group
Value
95% CI
Flavor
3.30
± 1.61
Relative Reinforcing Value of Cigarillo FlavoringPrimary· Laboratory visit 2 (Day 2, 2 hours)
Relative reinforcing value of cigarillo flavoring will be measured with a validated choice paradigm, evaluating the preference for sweet flavored (the cigarillo with the highest rewarding value measured in visit 1) relative to non-flavored cigarillos. The reinforcement schedule in the non-flavored cigarillo remained constant at a fixed ratio FR-25, while the reinforcement schedule for the sweet-flavored cigarillo increased with a progressive ratio schedule of PR-25x over 10 trials. RRVF will be defined by the breakpoint (highest trial completed across 10 trials to earn puffs for sweet flavored
Sweet flavored
Group
Value
95% CI
Flavor
6.34
5.98 – 6.70
Non-flavored
Group
Value
95% CI
Flavor
3.66
3.30 – 4.02
Absolute Reinforcing Value of Cigarillo FlavoringPrimary· Laboratory visit 3 (Day 3, 2.5 hours)
Absolute reinforcing value of cigarillo flavoring is operationalized as the number of sweet flavored versus non-flavored cigarillo puffs consumed during the ad libitum smoking session. A research assistant will videotape, monitor, and count the number of cigarillo puffs taken during the 90-minute period. The primary comparison is the amount of consumption (puffs) of the sweet flavored (determined at visit 1) versus non-flavored cigarillo. A greater number of puffs indicates a higher absolute reinforcing value. Primary Outcome measured at visit 3.
Sweet flavored
Group
Value
95% CI
Flavor
40.88
37.74 – 44.03
Non-flavored
Group
Value
95% CI
Flavor
23.12
20.25 – 25.98
Adverse events — posted to ClinicalTrials.gov
Time frame: 3 weeks.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Flavor
Serious: 0/86 (0%)
Deaths: 0/86
Other adverse events (1 terms — click to expand)
Reaction
System
Flavor
Participant vomited in smoking lab sink after taking cigarillo puffs during Lab visit 2.
This within-subjects study aims to evaluate the subjective rewarding value, the relative reinforcing value, and the absolute reinforcing value of sweet flavored cigarillos across three separate laboratory visits among 86 young adults (ages 18-24 years old) who have previously smoked \> 10 or more cigarillos in their lifetime.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06506162 — Abuse Liability and Appeal of Oral Nicotine Products
· NA
· recruiting
NCT05836051 — Testing the Effect of ENDS Flavors on Neurotransmission
· NA
· completed
NCT03635333 — Effects of E-Cigarette Flavors on Adults TCORS 2.0
· Phase 1
· completed
Other recruiting trials for Tobacco Use
Currently open trials in the same condition.
NCT07162935 — Cigar Legislation and Regulation in Tobacco for the Young (Project CLARITY)
· NA
· recruiting
NCT07132814 — Abuse Liability for Five Modern Oral Nicotine Products
· NA
· recruiting
NCT07148232 — Extended Intervention for Tobacco Use (EXIT) for People Experiencing Homelessness
· Phase 4
· recruiting
NCT06983678 — Neural Correlates and Behavioral Impact of Withdrawal-induced Hyperalgesia Among People Who Smoke With and Without Chron
· NA
· recruiting
NCT06922617 — STEPS: Substance Use Trial of E-cigarettes or Pharmacotherapy for Smoking
· NA
· recruiting
Other University of Pennsylvania trials
Trials by the same sponsor.
NCT06081153 — Mechanistic Clinical Trial of PCSK9 Inhibition for AAA
· EARLY_PHASE1
· not yet recruiting
NCT07415772 — Effect of cTBS on Startle and TMS-evoked BOLD
· NA
· not yet recruiting
NCT07489430 — DaxibotulinumtoxinA for Blepharospasm
· Phase 2
· not yet recruiting
NCT07463131 — Negative Income Tax Trial
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Pennsylvania
Last refreshed: 17 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05092919.